Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
Institut Pasteur Korea · Novartis (Singapore) · +9 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
610
total citations
- FWCI
- 20.66
- Percentile
- 100%
- References
- 36
Citations per year
Authors
55Topics & keywords
Topics
Keywords
- Tuberculosis
- Medicine
- Extensively drug-resistant tuberculosis
- Mycobacterium tuberculosis
- Pharmacology
- Dosing
- Bedaquiline
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.